Demonstrates improved access to therapeutic drug monitoring in tuberculosis treatment, suggesting enhanced patient care.
Extract In this issue of the European Respiratory Journal, Nguyen et al. [1] report methods to improve the accessibility of therapeutic drug monitoring (TDM) during tuberculosis (TB) treatment. The study describes a point-of-care TDM method for saliva samples to measure linezolid (an oxazolidinone) and levofloxacin (a fluoroquinolone), two active drugs to treat multidrug-resistant Mycobacterium tuberculosis.
No takes yet. Share an insight, caveat, or question.
Srivastava et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: